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INTRODUCTION
Stenting of de novo lesions in native coronary arteries is an established and effective treatment of coronary narrowing due to atherosclerosis. However, long term efficacy of bare metal stents (BMS) has been hampered by the development of restenosis, resulting in rehospitalization for percutaneous or surgical revascularization in 10-20% of patients 1 . Drug eluting stents (DES) have been shown to be effective against restenosis by reducing neointimal hyperplasia after vascular injury, as compared to BMS. 2 The objective of the SPIRIT II trial was to evaluate the safety and performance of the everolimuseluting coronary stent (XIENCE V, Abbott Vascular, Santa Clara, CA) compared with the paclitaxel eluting coronary stent (TAXUS EXPRESS2 or Liberte, Boston Scientific, Natick, MA) in the treatment of de novo native coronary artery lesions. The everolimus eluting stent (EES) is comprised of the ACS MULTI-LINK VISION stent and delivery system, and a drug-eluting coating. Everolimus, an analogue of rapamycin, is a powerful antiproliferative agent that blocks cell cycle progression between the G1 and S phases, inhibiting smooth muscle cell proliferation. 3 The feasibility of the EES was first demonstrated in the FUTURE-I and FUTURE II studies and more recently in the SPIRIT FIRST study which demonstrated both clinical safety and efficacy. 4, 5, 6, 7 In the SPIRIT FIRST study, the clinical outcome at two-year follow-up was in favour of the EES group compared with the BMS group but did not reach statistical significance due to small patient numbers. In the current trial, the EES performed superior to the paclitaxel-eluting stent (PES) regarding angiographic late loss at six months (0.11±0.27mm versus 0.36±0.39mm). Furthermore intravascular ultrasound (IVUS) results showed that the EES was more effective at reducing neointimal hyperplasia; both percentage volume obstruction (%VO) and neointimal hyperplasia volume (NIH) were significantly lower in patients treated with EES. 8 The incidence of target lesion failure (TLF) was low and comparable between groups at six months (2.7% for EES versus 6.5% for PES). At one year, there was a significant benefit in TLF favoring the EES (2.7% versus 9.2%). 9 This report focuses on the two-year clinical outcomes of all patients enrolled in the SPIRIT II trial and the angiographic and IVUS follow-up in a subset of patients.
METHODS

Study Population
The study design of the SPIRIT II trial has been previously described. 8, 9, 10 In brief, this prospective, randomized (3:1) single blind, parallel two-arm trial was performed at 28 centers in Europe, India and New Zealand and randomized 300 patients in a 3:1 ratio to either an EES (n=223) or a PES (n=77) between July 2005 and November 2005. The study protocol was approved by the ethics committee at each participating institution, and all patients gave written informed consent. Patients enrolled in the study were older than 18 years with evidence of myocardial ischemia and had a maximum of two de novo native coronary artery lesions, located in different major epicardial vessels. Target lesion(s) had to comply with the following inclusion criteria: a reference vessel diameter between 2.5mm and 4.25 mm by visual estimation, a target lesion length ≤28 mm, a visually estimated stenosis between 50-99% of the luminal diameter, and a Thrombolysis In Myocardial Infarction flow grade of 1 or more. Patients were excluded from enrollment if they had documented acute myocardial infarction within three days prior of the baseline procedure, a left ventricular ejection fraction <30%, were awaiting a heart transplant, or had a known hypersensitivity or contraindication to aspirin, heparin, bivalirudin, clopidogrel or ticlopidine, cobalt, chromium, nickel, tungsten, everolimus, paclitaxel, acrylic and fluoropolymers. Angiographic exclusion criteria were target lesion(s) within 2 mm of the origin of the left anterior descending or left circumflex coronary artery, heavy calcification, or a visible thrombus within the target vessel.
Study Procedure
Following the confirmation of angiographic in-and exclusion criteria prior to the procedure, patients were randomized through a telephone call to either an EES or a PES. Due to packaging differences, operators were not blinded to the device. Lesions were treated using standard interventional techniques with mandatory pre-dilatation and stent implantation pressure not exceeding the burst pressure rate. Post-dilatation was left to the discretion of the physician, and if performed was only to be done with balloons sized to fit within the boundaries of the stent. In the event of a bailout procedure and additional stent requirement, the stent had to be one from the same group as the first implanted stent. At baseline, IVUS was performed in a subset of 152 consecutive patients enrolled in pre-selected centers, after angiographically optimal stent placement had been obtained. IVUS was repeated if additional post-dilatation was performed to optimize stent apposition and/ or deployment. Patient preparation and pharmaceutical treatment during the hospital procedure were to be in accordance with standard hospital practice. The use of GPIIb/IIIa inhibitors was left to the discretion of the physician. All patients were to receive 75 mg clopidogrel for a minimum of six months and ≥75 mg of aspirin daily for a minimum of one year following procedure. 
Follow-up
Clinical follow-up was scheduled at 30, 180, 270 days and one and two years with further evaluations planned at three, four, and five years by protocol amendment. At outpatient visits, patients were asked specific questions about the interim development of angina or the occurrence of adverse events. Angiographic follow-up was planned at 180 days for all patients. In the subset of 152 consecutive patients (enrolled in selected centers) IVUS was planned at 180 days and both IVUS and angiographic follow-up were to be repeated at two years. There was a 28 day window for the visit at two years.
Clinical endpoints
The clinical part of this two year follow-up study focuses on TLF (cardiac death, myocardial infarction and ischemia-driven target lesion revascularization either by CABG or PCI -defined as major adverse cardiac events in the study protocol). Secondary clinical endpoints included target vessel failure (cardiac death, myocardial infarction (MI) and ischemia-driven target vessel revascularization), target lesion revascularization, target vessel revascularization and stent thrombosis. All clinical endpoints were adjudicated by a blinded clinical events committee (CEC). All deaths that could not be clearly attributed to a non-cardiac cause were considered cardiac deaths. Q-Wave MI was defined as development of new pathological Q waves. Non-Q-wave myocardial infarction was defined as a typical rise and fall of CK-MB with at least one of the following: ischemic symptoms, electrocardiographic changes indicative of ischemia, or associated with a coronary artery intervention. For non-procedural/spontaneous MI, CK-MB had to be ≥ 2 times upper limit of normal, for post PCI ≥ 3 times upper limit of normal, and for post coronary artery bypass grafting ≥ 5 times upper limit of normal. For each MI, the relationship to the target vessel was adjudicated by the CEC. Ischemia-driven target lesion revascularization (ID-TLR) was defined as a revascularization at the target lesion associated with any of the following: a positive functional ischemia study (exercise testing, fractional flow reserve or coronary flow reserve), ischemic symptoms and an angiographic diameter stenosis ≥50% by core lab Quantitative Coronary Angiography (QCA); or a diameter stenosis ≥70% by core lab QCA without ischemic symptoms or a positive functional study. Stent thrombosis was categorized according to the definitions proposed by the Academic Research Consortium (ARC) for definite, probable and possible stent thrombosis.
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Angiographic endpoints
The angiographic part of this paper focuses on in-stent late loss at two years (in the subset of 152 patients). Secondary angiographic endpoints include in-segment late loss, proximal and distal late loss, in-stent and in-segment percentage diameter stenosis and angiographic binary restenosis. QCA was performed using the CAAS II analysis system (Pie Medical BV, Maastricht, The Netherlands) by an independent core laboratory (Cardialysis B.V., Rotterdam, The Netherlands) with observers blinded to treatment assignment. In each patient, the stented segment and the peri-stent segments (defined by a length of 5 mm proximal and distal to the stent edge) were analyzed. The following QCA parameters were computed: minimal luminal diameter, reference vessel diameter obtained by an interpolated method, and percentage diameter stenosis. Binary restenosis was defined in every segment as a diameter stenosis ≥50% at follow-up. Late loss was defined as the difference between minimal luminal diameter post-procedure and minimal luminal diameter at follow-up. If a patient underwent target lesion revascularization before the scheduled two-year angiography, QCA was performed on the pre-interventional angiography and its results were imputed into two-year follow-up angiography outcomes.
Intravascular ultrasound endpoints
The IVUS part of this paper focuses on percentage in-stent volume obstruction at two years (in the subset of 152 patients). Secondary IVUS endpoints include in-stent neointimal volume and vessel, stent and lumen volumes. Post-procedure and follow-up stented vessel segments were examined with mechanical or phased array intravascular ultrasound (Eagle-eye tm Volcano, Rancho Cordova, CA, Atlantis tm, Boston
Scientific, Natick, MA) using automated pull-back at 0.5 mm per second after administration of 0.2mg intracoronary nitroglycerin. The coronary segment beginning 5 mm distal to and extending 5 mm proximal to the stented segment was examined. IVUS analyses were also performed by an independent core laboratory (Cardialysis B.V., Rotterdam, The Netherlands) with observers blinded to treatment assignment. A computer-based contour detection program was used for automated 3-D reconstruction of the stented and adjacent segments. The lumen, stent boundaries and external elastic membrane (vessel boundaries) were detected using a minimum cost algorithm. 12 The stent volume and lumen volume were calculated according to Simpson's rule. 13 The in-stent neointimal volume was calculated as the difference between stent volume and lumen volume. The percentage obstruction of the stent volume was calculated as intrastent neointimal volume/stent volume*100. Feasibility, reproducibility and inter-and intra-observer variability of this system have been validated in vitro and in vivo. 13 Incomplete apposition was defined as one or more stent struts separated from the vessel wall with evidence of blood speckles behind the strut on ultrasound, while late-acquired incomplete apposition was defined as incomplete apposition of the stent at follow-up which was not present post-procedure. 14, 15, 16 
Statistical methods
Final two-year results are presented in this manuscript. Six-month results in patients whose twoyear results were available are presented for comparative purposes. (These results may differ from those in previous publications with more patients) Binary variables are presented as percentages and compared using the Fisher's exact test. Continuous variables are presented as mean±standard deviation and compared using the Student's T-test. Confidence intervals for the differences are based on normal assumption. Non-inferiority p-values for in-stent Late-Loss in the subset of lesions with serial 6 months and 2 years measurements are calculated with a one-sided asymptotic test and were not predefined in the protocol. The non-inferiority margin used for those tests is 0.16mm, 1.06 ± 0.42 1.14 ± 0.36 Diameter stenosis, mean ± SD (%) 61 ± 12 59 ± 10 Lesion length, mean ± SD (mm)
13.0 ± 5.7 13.2 ± 6.4 EES = Everolimus Eluting Stent, PES = Paclitaxel eluting stent There were no significant differences in baseline variables between the groups, with the exception of a smaller MLD in the EES group (p=0.03) Chapter 
log-rank test. Data on patients who were lost to follow-up were censored at the time of the last contact. Data on patients who died of non-cardiac causes were censored at the time of death. Statistical analyses were performed using SAS version 9.1.3 (SAS Institute Inc, Cary, North Carolina)
RESULTS
Patients and enrollment
Two-year clinical follow-up was available for 211 of the 223 patients (94.6%) in the EES group and in 73 of the 77 patients (94.8%) of the PES group.(figure 1) In the EES group, 4 patients withdrew, 1 patient was lost to follow-up, and 7 patients died from a non-cardiac cause. In the PES group with no patients lost to follow-up, 4 patients died from a non-cardiac cause. Baseline demographic, clinical and angiographic characteristics of the treatment groups have previously been reported and are summarized in table 1. 8 There were no significant differences between treatment groups in any of the tabulated characteristics, with the exception of a smaller MLD in the EES group (p=0.03). Of the subset of 152 patients in the angiography and IVUS subgroup, a further subset of 115 patients underwent serial and analyzable angiography (EES, 97 lesions, 83 patients, 73%, PES, 35 lesions, 32 patients, 82%) and 95 patients underwent serial and analyzable IVUS (EES, 69 lesions, 64 patients, 57%, PES, 32 lesions, 31 patients, 79%). The angiography and IVUS patient subgroup was comparable with the total cohort. (Data not shown) There were no differences in baseline characteristics between the EES and PES patient groups in the angiography and IVUS subset of patients with the exception of a higher prevalence of previous myocardial infarction in the EES patient group (EES: 42%, PES: 18%, p<0.01) and a smaller MLD in the EES group (p=0.01). Table 2 shows TLF at two years and each of its components. At two years, TLF occurred in 6.6% of the EES group compared with 11.0% in the PES group. In each treatment group, one patient died of a cardiac cause (0.5 vs 1.4%). The incidence of MI at two years was 2.8% (6 patients) and 5.5% (4 patients) in the EES and PES groups, respectively. Ischemia driven-TLR comprised the majority of TLF within both groups with 3.8% (8 patients) and 6.8% (5 patients) in the EES and PES groups, respectively. The temporal distribution of TLF and its component events is shown in Kaplan-Meier curves (figure 2). Although TLF rates in the EES group are consistently lower, the significant separation in TLF rate observed at one year was not maintained at two year follow-up (p logrank =0.223).
Clinical outcomes
Definite or probable stent thrombosis occurred once in two patients (0.9%) in the EES treatment group and twice in one patient (1.4%) in the PES treatment group. Both the stent thromboses in the everolimus group occurred after one year. Characteristics of the stent thrombosis episodes are shown in table 3.
Angiographic outcomes
Angiographic results from 132 lesions in the subset of 115 patients who underwent serial angiography at 6 months and 2 years are shown in table 4. Two year mean in-stent late loss was 0.33±0.37mm for the EES group and 0.34±0.34mm for the PES group (p=0.84) against 0.17±0.32 and 0.33±0.32 (p=0.01) at six months. If we would apply the non-inferiority margin prespecified for the analysis of the primary endpoint at six months of 0.16mm, the results at two years would still show non-inferiority (post-hoc analysis) 8 . Figure 3 shows the cumulative distribution frequency curve of in-stent late loss at six month and two year follow-up. Proximal and distal mean late loss were 0.24±0.49 and 0.08±0.38 respectively for EES and 0.33±0.45 and 0.11±0.40 for PES. Mean instent percent diameter stenosis was 19.21±14 in the everolimus group compared to 18.76±11 in the paclitaxel group (p=0.85). Two-year in-stent angiographic binary restenosis rate was 2.1% for EES and 2.9% for PES (p=1.000).
Intravascular ultrasound outcomes
IVUS results from 101 lesions in 95 patients who underwent IVUS at six months and two years are shown in table 5. IVUS evaluation at two year follow-up showed no significant differences in % volume obstruction between EES and PES treatment groups. Mean % volume obstruction was 5.18 ± 6.22 versus 5.80 ± 6.31 (p=0.65) for EES and PES, respectively. Similarly, the neointimal hyperplasia volume at two years did not differ between both groups. Mean neointimal hyperplasia volume was 8.42 ± 10.25mm 3 in the everolimus group and 11.56 ± 16.12mm 3 in the paclitaxel group. IVUS evaluation showed no significant differences between EES and PES with respect to vessel, stent and lumen volumes at two years.
DISCUSSION
This paper reports the two-year clinical, angiographic and IVUS follow-up of the EES compared with the PES in patients with a maximum of two de novo coronary artery lesions. The results of this trial confirm the efficacy of the EES from earlier results reported in the FUTURE I and II, SPIRIT FIRST, II, and III studies. 6, 7, 10, 4, 8, 9, 17 In addition, this is the first study that provides two year angiographic and IVUS data for the EES. Two year TLF rates in the current trial were 6.6% for the EES and 11.0% for the PES (p=0.31).
To date, results from one other randomized clinical trial comparing EES and PES are available. The large-scale SPIRIT III trial enrolled 1002 patients in North America with a maximum of two de novo coronary artery lesions who were randomized 2:1 to EES or PES. Inclusion-and exclusion criteria were similar to the SPIRIT II trial. As a result baseline variables were comparable between both trials; mean lesion length was 13.0mm and 14.7mm, mean reference vessel diameter was 2.7mm and 2.8mm for SPIRIT II and SPIRIT III, respectively. 9, 17 In the SPIRIT III trial, at two years, TLF rates remained significantly lower for the EES; 7.7% for EES and 13.8% for PES (p=0.005) 18 , with continued divergence of the event rates between one and two years. The reduced TLF rate in the EES group was attributable to fewer non-Q wave myocardial infarctions and target lesion revascularizations. Although the difference in two year TLF rate did not reach statistical significance in the current SPIRIT II trial, a trend in favor of the EES was observed. The results of the SPIRIT III trial indicate that this non-significance is most likely due to the lower number of patients enrolled in SPIRIT II.
The incidence of definite or probable stent thrombosis as defined by the ARC 11 was 0.9% for EES and 1.4% for PES after two years in the current study. Two-year stent thrombosis rates have been reported for 3 randomized trials evaluating the EES, SPIRIT FIRST, II, and III. 4, 18 In these 3 trials combined, two year follow-up data were available for 866 patients treated with an EES. The occurrence of stent thrombosis was low; in total, 10 patients (1.2%) had suffered a definite or probable stent thrombosis within two year follow-up, indicating the safety of the EES up to two years follow-up. It must be born in mind that definitive statements about long-term safety of the EES can only be made after the results of larger registries have become available.
Angiographic and IVUS data of DES are limited beyond 6-9 month follow-up. At six month followup, in the subgroup with six month and two year angiography from the SPIRIT II trial the in stent late loss was 0.17±0.32 mm in the EES group and 0.33±0.32 mm in the PES group (p=0.01). Furthermore, significant differences in neointimal hyperplasia volume (4.13±6.77mm 3 vs 12.62±16.77 mm 3 ,
264 Chapter 19 p<0.01) and % volume obstruction (2.77±5.02% versus 6.48±6.69%, p<0.01) in favor of the EES were observed. At two years, delayed neointimal hyperplasia was observed in the EES group with an in-stent late loss measured by QCA of 0.33±0.37mm, whereas the late loss measured in the PES group was maintained (0.34±0.34 mm, p=0.6). IVUS measurements were in accordance with this as we no longer observed significant differences in neointimal hyperplasia volume (EES: 8.42±10.25 mm 3 , PES: 11.56±16.12 mm 3 ) and % volume obstruction (EES: 5.18±6.22%, PES: 5.80±6.31%) at two years. Given the small number of late TLR's in this study one can only speculate whether the delayed neointimal hyperplasia in the EES group did lead to an increase in TLR. Our results are in line with the results from the TAXUS II trial, comparing slow (SR)-and moderate release (MR) PES to a BMS in patients with a single de novo coronary artery lesion, in which six month and two year angiographic and IVUS follow-up was obtained in a subset of 155 event-free patients. 14, 19 Angiographic late loss in the PES group was 0.25±0.30 mm at two years which was not different compared to six month late loss (0.29±0.32 mm) and is consistent with the findings reported in this paper. Neointimal volume measured by IVUS increased significantly from six months to two years for the PES treatment group while a trend towards a decrease was observed in the BMS group. This is inconsistent with IVUS observations in the current trial, where neointimal volume remained unchanged in the PES group between 6 months and two years. Patients in the PES treatment group in the TAXUS II trial were treated with a less advanced stent platform (NIR stent platform) with two different drug release kinetics (SR and MR) which could explain this discrepancy.
Previous animal studies already showed that despite marked early suppression of neointimal formation, late neointimal growth occurs within DES. In a porcine coronary artery model, long term inhibition of neointimal formation after Sirolimus eluting stent (SES) placement was not maintained partly due to inflammation and delayed cellular proliferation. In addition, after PES placement similar findings were found with delayed healing and local toxicity after high dose paclitaxel which was associated with delayed intimal formation. 20, 21 In vivo, the explanation for the delayed neointimal growth is multifactorial. In addition to an inflammatory response, shear stress-mediated remodeling could also attribute to the late "catchup" phenomenon observed in the EES group. 22 Shear stress is a primary signal for neointimal growth and is defined as the frictional force at the endothelial surface produced by flowing blood. Regions with low shear stress in the treated coronary segment have been found to be predisposed for neointimal growth. 22 Differences in stent design could have led to different distributions of shear stress after stent placement. Finally, the differences in polymer and pharmacological release kinetics between both stent types could be another explanation. Everolimus is blended into an 8-µm-thick durable fluoropolymer layer, approximately 75% of the drug on the EES is released within 30 days after implantation. Paclitaxel is blended into an 18-µm-thick polymer layer, during the first 48 hours after PES implantation there is an initial burst release followed by ten days of continuous drug release.
The longest available angiographic and IVUS follow-up after drug-eluting stent implantation (SES) is four years. From two to four years, neointimal growth was still observed. However, delayed restenosis after DES implantation does not seem to have clinical significance as both PES and SES markedly reduce target-lesion-and target-vessel revascularization after four years. 2 We will have to await the three, four, and five years clinical follow-up for the SPIRIT II and III studies to evaluate the long term clinical implications for the EES. A preliminary analysis of the 3 year data from SPIRIT II has in fact shown significantly lower cardiac death and TLF event rates, and lower observed MI and ID-TLR rates for EES compared to PES (ACC 2009 abstract) 23 . Furthermore, the performance of The P value for non-inferiority of the EES at two years is 0.005 (non pre-specified analysis in this subgroup) the EES will be evaluated in more complex patients in the SPIRIT IV, V, XIENCE V SPIRIT Women, and XIENCE V USA studies.
Study Limitations
This trial was not powered to detect significant differences in the safety profiles of PES and EES. Given the low frequency of the stent thromboses (3 patients total in this trial), no conclusions can be made about the relative safety profile of these stents. Furthermore, this was a single blind trial. The operator was aware of the type of stent being implanted. However, it is unlikely that knowledge of the stent type would have influenced the operators' decisions to reintervene. Angiographic data were obtained on roughly half the cohort; serial analyses were performed on a further subset. Finally, we need more prolonged clinical follow-up to establish whether the late neo-intimal catchup observed in the EES treatment group translates into an increased revascularization rate.
CONCLUSION
Although the previously reported angiographic and clinical superiority of the EES has vanished over time, this report confirms and extends the previously demonstrated non-inferiority in terms of in-stent late loss of the EES as compared to the PES up to two year follow-up. There were no significant differences between EES and PES in clinical, angiographic and IVUS outcomes at two years.
